Jeffrey A Cohen

List of Publications by Year
in descending order

156 papers	27,495 citations	36303 51 h-index	9589 142 g-index
160 all docs	160 docs citations	160 times ranked	19607 citing authors

#	Article	IF	Citations
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
2	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
3	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
4	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 402-415.	27.0	1,983
5	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	13.7	1,041
6	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	13.7	1,040
7	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Multiple Sclerosis Journal, 2008, 14, 383-390.	3.0	535
8	A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature, 1989, 339, 230-231.	27.8	432
9	Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine, 2020, 383, 546-557.	27.0	358
10	Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Annals of Neurology, 2011, 69, 759-777.	5.3	344
11	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281.	3.0	273
12	Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 704-710.	3.0	270
13	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet, The, 2017, 389, 1357-1366.	13.7	235
14	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
15	Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurology, The, 2012, 11, 467-476.	10.2	211
16	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurology, The, 2011, 10, 520-529.	10.2	204
17	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
18	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188

#	Article	IF	Citations
19	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
20	Vision and vision-related outcome measures in multiple sclerosis. Brain, 2015, 138, 11-27.	7.6	168
21	Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial. Archives of Neurology, 2001, 58, 961.	4.5	151
22	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 373-381.	10.2	150
23	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
24	Long-term (up to 4.5â€...years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 468-475.	1.9	137
25	Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology, 2014, 82, 674-680.	1.1	135
26	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293.	3.0	131
27	Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1781-1790.	3.0	129
28	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology, 2015, 84, 784-793.	1.1	119
29	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs, 2015, 29, 565-575.	5.9	117
30	Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet, The, 2021, 398, 1184-1194.	13.7	113
31	Mesenchymal stem cell transplantation in multiple sclerosis. Journal of the Neurological Sciences, 2013, 333, 43-49.	0.6	110
32	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
33	Combination therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 299-308.	10.2	106
34	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Multiple Sclerosis and Related Disorders, 2014, 3, 494-504.	2.0	105
35	Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics, 2017, 14, 859-873.	4.4	105
36	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 94-105.	3.0	95

#	Article	IF	Citations
37	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurology, The, 2020, 19, 336-347.	10.2	90
38	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 501-511.	3.0	86
39	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology, 2013, 260, 2023-2032.	3.6	82
40	The Potential for Vigabatrin-Induced Intramyelinic Edema in Humans. Epilepsia, 2000, 41, 148-157.	5.1	75
41	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Translational Medicine, 2016, 5, 1506-1514.	3.3	73
42	The 2013 clinical course descriptors for multiple sclerosis. Neurology, 2020, 94, 1088-1092.	1.1	73
43	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Annals of Neurology, 2010, 68, 540-545.	5.3	69
44	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 845-854.	2.0	69
45	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Multiple Sclerosis and Related Disorders, 2014, 3, 629-638.	2.0	68
46	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. JAMA Neurology, 2015, 72, 1433.	9.0	67
47	Phase III doseâ€comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 2011, 69, 75-82.	5.3	65
48	Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine, 2012, 63, 389-404.	12.2	64
49	Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 2016, 86, 1446-1453.	1.1	64
50	Multiple sclerosis management during the COVID-19 pandemic. Multiple Sclerosis Journal, 2020, 26, 1163-1171.	3.0	63
51	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology, 2019, 93, e1921-e1931.	1.1	58
52	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
53	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.1	55
54	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Multiple Sclerosis Journal, 2020, 26, 23-37.	3.0	55

#	Article	IF	Citations
55	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832.	3.5	54
56	COVID-19 in people with multiple sclerosis: A global data sharing initiative. Multiple Sclerosis Journal, 2020, 26, 1157-1162.	3.0	50
57	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. Journal of the American College of Radiology, 2017, 14, 371-379.e1.	1.8	49
58	The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology, 2016, 86, 1437-1445.	1.1	48
59	Early tolerability and safety of fingolimod in clinical practice. Journal of the Neurological Sciences, 2012, 323, 167-172.	0.6	44
60	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis and Related Disorders, 2016, 10, 44-52.	2.0	43
61	Fingolimod Therapy for Multiple Sclerosis. Seminars in Neurology, 2013, 33, 037-044.	1.4	42
62	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsingâ€"Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1704-1713.	3.0	41
63	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis Journal, 2018, 24, 1469-1484.	3.0	41
64	Multiple sclerosis symptom management. Expert Review of Neurotherapeutics, 2007, 7, 1213-1222.	2.8	39
65	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341.	3.0	39
66	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
67	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis â€" Authors' reply. Lancet Neurology, The, 2018, 17, 499-500.	10.2	35
68	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. Annals of Neurology, 2020, 88, 81-92.	5.3	33
69	Clinical outcome measures for progressive MS trials. Multiple Sclerosis Journal, 2017, 23, 1627-1635.	3.0	32
70	Experience with fingolimod in clinical practice. International Journal of Neuroscience, 2015, 125, 678-685.	1.6	31
71	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials, 2020, 95, 106009.	1.8	31
72	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon Î²-1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28

#	Article	IF	Citations
73	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731771548.	1.0	28
74	Emerging Therapies for Relapsing Multiple Sclerosis. Archives of Neurology, 2009, 66, 821-8.	4.5	27
75	Safety of monoclonal antibodies for the treatment of multiple sclerosis. Expert Opinion on Drug Safety, 2017, 16, 89-100.	2.4	27
76	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	27
77	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. CNS Drugs, 2021, 35, 985-997.	5.9	26
78	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1423-1437.	2.0	25
79	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurology: Clinical Practice, 2018, 8, 292-301.	1.6	25
80	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal, 2022, 28, 1562-1575.	3.0	25
81	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Multiple Sclerosis Journal, 2017, 23, 1909-1917.	3.0	23
82	Movement disorders in early MS and related diseases. Neurology: Clinical Practice, 2019, 9, 24-31.	1.6	22
83	Alemtuzumab for the treatment of relapsingâ€“remitting multiple sclerosis. Immunotherapy, 2014, 6, 249-259.	2.0	20
84	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673.	2.0	20
85	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19
86	Emerging Oral Therapies in Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2010, 10, 381-388.	4.2	18
87	Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110571.	1.0	16
88	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	3.0	16
89	Multiple sclerosis, porphyria-like symptoms, and a history of iron deficiency anemia in a family of Scottish descent. , 1999, 86, 194-196.		15
90	Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102454.	2.0	15

#	Article	IF	Citations
91	Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Review of Clinical Pharmacology, 2011, 4, 567-570.	3.1	14
92	Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology, 2014, 83, 192-194.	1.1	14
93	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences, 2019, 407, 116498.	0.6	14
94	CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. Experimental Neurology, 2017, 295, 222-232.	4.1	13
95	Developing therapeutic strategies to promote myelin repair in multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 997-1013.	2.8	13
96	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Multiple Sclerosis Journal, 2020, 26, 1581-1589.	3.0	13
97	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal, 2022, 28, 1131-1137.	3.0	13
98	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurology: Clinical Practice, 2020, 10, 222-231.	1.6	12
99	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology, 2021, 28, 3722-3730.	3.3	12
100	Clemastine fumarate for promotion of optic nerve remyelination. Lancet, The, 2017, 390, 2421-2422.	13.7	11
101	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 38, 101525.	2.0	11
102	Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. Lancet Neurology, The, 2011, 10, 4-5.	10.2	10
103	Handbook of Multiple Sclerosis. , 2012, , .		9
104	Venous angioplasty for â€œCCSVIâ€•in multiple sclerosis. Neurology, 2014, 83, 388-389.	1.1	8
105	Fingolimod failure in progressive MS INFORMS future trials. Nature Reviews Neurology, 2016, 12, 253-254.	10.1	8
106	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985603.	1.0	8
107	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2019, 25, 601-609.	3.0	8
108	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 2022, 269, 1786-1801.	3.6	8

#	Article	IF	Citations
109	Women's Health in Multiple Sclerosis: A Scoping Review. Frontiers in Neurology, 2021, 12, 812147.	2.4	8
110	How effective is intravenous immunoglobulin for the treatment of relapsingâ€"remitting multiple sclerosis?. Nature Clinical Practice Neurology, 2008, 4, 588-589.	2.5	7
111	The future of multiple sclerosis treatment. Journal of the Neurological Sciences, 2009, 277, S55-S61.	0.6	7
112	Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876528.	1.0	7
113	Lymphocyte counts and infection rates. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	7
114	The emergence of follow-on disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1560-1565.	3.0	7
115	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988719.	1.0	7
116	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989174.	1.0	7
117	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2219-2231.	3.0	7
118	Perspectives and experiences with COVID-19 vaccines in people with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210852.	1.0	7
119	Fingolimod. Neurology: Clinical Practice, 2011, 1, 61-65.	1.6	6
120	Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations. EBioMedicine, 2018, 29, 5-6.	6.1	6
121	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis and Related Disorders, 2019, 36, 101335.	2.0	6
122	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. Neurology, 2020, 94, 273-275.	1.1	6
123	Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis. Drug Safety, 1996, 14, 121-130.	3.2	5
124	Integrating multiple sclerosis guidelines into practice. Lancet Neurology, The, 2018, 17, 658-660.	10.2	5
125	The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis. Neurotherapeutics, 2020, 17, 968-970.	4.4	5
126	Response of the multiple sclerosis community to COVID-19. Multiple Sclerosis Journal, 2020, 26, 1134-1136.	3.0	5

#	Article	IF	Citations
127	Continuing Clinical Research During <scp>Shelterâ€inâ€Place</scp>. Annals of Neurology, 2020, 88, 658-660.	5.3	5
128	The benefits and risks of alemtuzumab in multiple sclerosis. Expert Review of Clinical Immunology, 2013, 9, 189-191.	3.0	4
129	Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes. Multiple Sclerosis and Related Disorders, 2016, 9, 129-134.	2.0	4
130	Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2021, 27, 1749-1759.	3.0	4
131	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	1.6	4
132	Treatment Challenges in Multiple Sclerosis â€“ A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	2.4	4
133	Switching sidesâ€”fingolimod versus injectable MS therapies. Nature Reviews Neurology, 2015, 11, 316-317.	10.1	3
134	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	1.0	3
135	Keep the Worms in the Mud. JAMA Neurology, 2020, 77, 1066.	9.0	3
136	Measurement of CNS atrophy. , 0, , 128-149.		2
137	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal, 2022, 28, 817-830.	3.0	2
138	Appraisal of the multiple sclerosis functional composite. Expert Review of Neurotherapeutics, 2003, 3, 335-341.	2.8	1
139	Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice. Multiple Sclerosis Journal, 2014, 20, 1280-1281.	3.0	1
140	Comorbidities in MS are associated with treatment intolerance and disability. Neurology, 2017, 89, 2218-2219.	1.1	1
141	Long-term ocrelizumab in progressive multiple sclerosis. Lancet Neurology, The, 2020, 19, 966-968.	10.2	1
142	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology: Clinical Practice, 2021, 11, 352-357.	1.6	1
143	MRI findings in blinded trials should be available to treating physicians â€“ No. Multiple Sclerosis Journal, 2021, 27, 814-815.	3.0	1
144	Multiple Sclerosis Wellness Shared Medical Appointment Model: A Pilot Study. International Journal of MS Care, 2021, 23, 229-233.	1.0	1

#	Article	IF	Citations
145	Early versus delayed treatment with glatiramer acetate: Analysis of up to 27â€‰years of continuous follow-up in a US open-label extension study. Multiple Sclerosis Journal, 2022, 28, 1729-1743.	3.0	1
146	Truncal ataxia presumably due to malignant spinal cord compression. Annals of Neurology, 1987, 21, 511-512.	5.3	0
147	Ligand Binding to the Cell-Surface Receptor for Reovirus Type 3 Alters Schwann Cell Growth and Function. Annals of the New York Academy of Sciences, 1990, 605, 412-415.	3.8	0
148	Assessment of neuropsychological function in multiple sclerosis. , 0, , 65-78.		0
149	The use of MRI in multiple sclerosis clinical trials. , 2011, , 198-212.		0
150	Treatment for patients with primary progressive multiple sclerosis. , 0, , 604-613.		0
151	Management of pediatric multiple sclerosis. , 0, , 632-644.		0
152	Management of medical comorbidities in patients with multiple sclerosis. , 0, , 714-723.		0
153	Fingolimod to treat multiple sclerosis. , 0, , 370-386.		0
154	Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?. Expert Review of Clinical Immunology, 2016, 12, 489-491.	3.0	0
155	Evolution of the Diagnostic Criteria in Multiple Sclerosis. , 2021, , 75-87.		0
156	Nursing, Diabetes, Hemodialysis and COVID-19. Journal of Religion and Health, 2022, 61, 1767-1771.	1.7	0